Disease progression by infecting HIV-1 subtype in a seroconverter cohort in sub-Saharan Africa
Open Access
- 13 November 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 27 (17), 2775-2786
- https://doi.org/10.1097/qad.0000000000000012
Abstract
Objective:To describe immunologic, virologic, and clinical HIV disease progression by HIV-1 subtype among Africans with well documented estimated dates of HIV infection (EDIs).Design:Prospective cohort.Methods:Adults and youth with documented HIV-1 infection in the past 12 months were recruited from seroincidence cohorts in East and Southern Africa and followed at 3-6 month intervals. Blood for lymphocyte subset and viral load determination was collected at each visit. Pol was sequenced from the first positive specimen to ascertain subtype. Preantiretroviral therapy disease progression was measured by three time-to-event endpoints: CD4(+) cell count 350cells/l or less, viral load measurement at least 1x10(5)copies/ml, and clinical AIDS.Results:From 2006 to 2011, 615 participants were enrolled at nine research centers in Kenya, Rwanda, South Africa, Uganda, and Zambia; 579 (94.1%) had viral subtyping completed. Predominant subtypes were C (256, 44.2%), A (209, 36.1%), and D (84, 14.5%). After adjustment for age, sex, and human leukocyte antigen alleles in Cox regression analyses, subtype C-infected participants progressed faster than subtype A to all three endpoints [CD4(+) hazard ratio 1.60, 95% (confidence interval) CI 1.16, 2.20; viral load hazard ratio 1.59, 95% CI 1.12, 2.25; and AIDS hazard ratio 1.60, 95% CI 1.11, 2.31). Subtype D-infected participants reached high viral load more rapidly (hazard ratio 1.61, 95% CI 1.01, 2.57) and progressed nearly twice as fast to AIDS compared to subtype A (hazard ratio 1.93, 95% CI 1.21, 3.09).Conclusion:Subtype-specific differences in HIV disease progression suggest that the local subtype distribution be considered when planning HIV programs and designing and defining clinical endpoints for HIV prevention trials.Keywords
This publication has 39 references indexed in Scilit:
- Adherence to Antiretroviral Therapy and Clinical Outcomes Among Young Adults Reporting High-Risk Sexual Behavior, Including Men Who Have Sex with Men, in Coastal KenyaAIDS and Behavior, 2013
- Role of Transmitted Gag CTL Polymorphisms in Defining Replicative Capacity and Early HIV-1 PathogenesisPLoS Pathogens, 2012
- Pilot Studies for Development of an HIV Subtype Panel for Surveillance of Global DiversityAIDS Research and Human Retroviruses, 2012
- Human Leukocyte Antigen Variants B*44 and B*57 Are Consistently Favorable during Two Distinct Phases of Primary HIV-1 Infection in Sub-Saharan Africans with Several Viral SubtypesJournal of Virology, 2011
- HIV-1 Viral Subtype Differences in the Rate of CD4+ T-Cell Decline Among HIV Seroincident Antiretroviral Naive Persons in Rakai District, UgandaJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- CLSI-Derived Hematology and Biochemistry Reference Intervals for Healthy Adults in Eastern and Southern AfricaPLOS ONE, 2009
- Short Communication: Viral Dynamics and CD4+ T Cell Counts in Subtype C Human Immunodeficiency Virus Type 1-Infected Individuals from Southern AfricaAIDS Research and Human Retroviruses, 2005
- No Difference in Clinical Progression between Patients Infected with the Predominant Human Immunodeficiency Virus Type 1 Circulating Recombinant Form (CRF) 02_AG Strain and Patients Not Infected with CRF02_AG, in Western and West‐Central Africa: A Four‐Year Prospective Multicenter StudyThe Journal of Infectious Diseases, 2002
- HIV-1 subtype C in BrazilThe Lancet, 1994
- Reduced Rate of Disease Development After HIV-2 Infection as Compared to HIV-1Science, 1994